Day One Biopharmaceuticals Inc (NASDAQ:DAWN) — Market Cap & Net Worth
Market Cap & Net Worth: Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) has a market capitalization of $1.13 Billion ($1.13 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8250 globally and #2413 in its home market, demonstrating a 0.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Day One Biopharmaceuticals Inc's stock price $21.53 by its total outstanding shares 102675502 (102.68 Million). See DAWN capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Day One Biopharmaceuticals Inc Market Cap History: 2021 to 2026
Day One Biopharmaceuticals Inc's market capitalization history from 2021 to 2026. Data shows change from $1.73 Billion to $2.21 Billion (-3.68% CAGR).
Index Memberships
Day One Biopharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.05% | #239 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #904 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.07% | #139 of 263 |
Weight: Day One Biopharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Day One Biopharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Day One Biopharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.92x
Day One Biopharmaceuticals Inc's market cap is 9.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $1.30 Billion | $131.16 Million | -$95.50 Million | 9.92x | N/A |
Competitor Companies of DAWN by Market Capitalization
Companies near Day One Biopharmaceuticals Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Day One Biopharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Day One Biopharmaceuticals Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Day One Biopharmaceuticals Inc's market cap moved from $1.73 Billion to $ 2.21 Billion, with a yearly change of -3.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.21 Billion | +131.01% |
| 2025 | $956.94 Million | -26.44% |
| 2024 | $1.30 Billion | -13.22% |
| 2023 | $1.50 Billion | -32.16% |
| 2022 | $2.21 Billion | +27.72% |
| 2021 | $1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Day One Biopharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more